Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPC

Arun Azad • 23 Oct 2023
ESMO 2023
Prostate Cancer Enzalutamide Talazoparib
TALAPRO-2

Arun Azad, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the exposure efficacy results from the Phase III TALAPRO-2 (NCT03395197) trial, elaborating on the treatment-related toxicities that accompany higher doses of talazoparib. Dr Azad comments on the need to find a healthy balance between optimal treatment efficacy and associated toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arun Azad

4:02
Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: findings from clinical trials
Arun Azad • 23 Oct 2023
4:15
Non-WT BRCA associated with inferior prognosis in patients with metastatic prostate cancer
Arun Azad • 23 Oct 2023
1:44
TALAPRO-2: exposure-safety of talazoparib + enzalutamide in mCRPC
Arun Azad • 23 Oct 2023
1:31
Prevalence of DDR alterations in patients with mHSPC enrolled in ARCHES: next steps
Arun Azad • 30 May 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals